Dose intensity and autologous stem cell transplantation as salvage therapy for pediatric primary CNS malignancies

Seiji Kojima,¹ Andrei Cucuianu,^2,3 Yoshiyuki Takahashi,¹ Ioana Berindan-Neagoe,^4–6 Ioan-Stefan Florian,⁷ Delia Dima,² Ciprian Tomuleasa<sup>2,4

1</sup>Department of Paediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; ²Department of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania; ³Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania; ⁴Department of Functional Genomics and Experimental Pathology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania; ⁵Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania; ⁶Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania; ⁷Department of Neurosurgery, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania


We have read with great interest the work of Lu et al published recently in the International Journal of Nanomedicine,¹ in which the authors describe different strategies for an efficient delivery of drugs to the central nervous system (CNS) across the blood–brain and blood–cerebrospinal fluid barriers. The paper describes in a very organized and efficient manner the current approaches to improve the penetration of various drugs across the blood–brain barrier, of key importance in CNS malignancies.

Read the original paper

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.